【光大医药&海外】金斯瑞生物科技(1548.HK):传奇生物扭亏在即,授权收入大幅增利

EBoversea
Aug 21, 2025

报告标题:《传奇生物扭亏在即,授权收入大幅增利——金斯瑞生物科技(1548.HK)2025年半年报点评》报告发布日期:2025年8月20日分析师:王明瑞(执业证书编号:S0930520080004)分析师:叶思奥(执业证书编号:S0930523050003)往期回顾【光大医药&海外】歌礼制药-B(1672.HK):持续聚焦代谢产品,打造差异化管线【光大医药&海外】石药集团(1093.HK):BD...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10